Updated:
BioAgilytix Labs
BioAgilytix Labs is a bioanalytical CRO led by CEO Davide Molho, serving 21 of the top 25 global pharma firms with labs in the US, Europe, and Australia.
BioAgilytix Labs
Discover the power of partnering with BioAgilytix's for your bioanalytical needs. Visit our site now for premier science and expert insights.
General information
Firm type
other
Location
Region
North America
Country
United States
City
Durham
Corporate office
Durham, NC, United States
Additional offices
Hamburg, Germany · Boston, MA, United States · San Diego, CA, United States · Melbourne, Australia
Principals
Davide Molho
Chief Executive Officer
Linda Robbie
Chief Operating Officer
Maureen Marchek
Chief Financial Officer
Amanda Hays
Scientific Officer
Lynn Kamen
Scientific Officer, Executive Director
Robert Nelson
Scientific Officer
Jessica Weaver
Scientific Officer
Sector focus
Frequently asked questions
Who makes investment decisions at BioAgilytix Labs?
BioAgilytix is not an investment firm; it is a contract research organization (CRO). Investment decisions regarding capital allocation and corporate strategy are made by CEO Davide Molho and the senior leadership team, which includes the chief financial officer, chief operating officer, and scientific officers (per the firm's leadership page).
Is BioAgilytix Labs a family office or asset manager?
No. BioAgilytix Labs is a bioanalytical testing services company, classified as a contract research organization (CRO). It does not manage third-party capital or operate as an investment vehicle. Its ownership structure is not publicly disclosed.
How does BioAgilytix source its scientific expertise?
The firm has grown through the acquisition of four bioanalytical laboratories and by hiring experienced scientists with PhDs and industry backgrounds. Its scientific office includes Amanda Hays, Lynn Kamen, Robert Nelson, and Jessica Weaver (per the firm).
What stages of drug development does BioAgilytix support?
BioAgilytix provides services across all phases: discovery, preclinical, clinical development, market launch, and post-market surveillance. Its services include assay development, validation, and sample testing for PK, immunogenicity, biomarkers, and CMC analytics (per the firm).
Which sectors does BioAgilytix serve?
The firm serves pharmaceuticals, biotechnology, biomedical technology, agricultural biotechnology, and animal health companies, ranging from emerging biotechs to top-25 global pharma (per the firm).
Does BioAgilytix have a philanthropic or foundation arm?
The firm's website mentions an ESG (Environmental, Social, and Governance) commitment, but no separate philanthropic foundation or structured giving program is publicly disclosed.
What is the relationship between BioAgilytix and 360biolabs?
360biolabs is a subsidiary of BioAgilytix, based in Melbourne, Australia, offering preclinical and clinical bioanalytical services. Its president, Alistair Draffan, and other executives are listed on the BioAgilytix leadership page (per the firm).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: